
Robert Mabry, Hillstar Bio CEO
Another immunology biotech emerges as Hillstar takes flight with $67M
The flurry of immunology biotech launches continues.
Boston-based Hillstar Bio on Tuesday became the latest immunology startup launch, unveiling a $67 million Series A round …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.